Lancet
-
Randomized Controlled Trial Meta Analysis Comparative Study Clinical Trial
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Imatinib is approved worldwide for use in gastrointestinal stromal tumours (GIST). We aimed to assess dose dependency of response and progression-free survival with imatinib for metastatic GIST. ⋯ If response induction is the only aim of treatment, a daily dose of 400 mg of imatinib is sufficient; however, a dose of 400 mg twice a day achieves significantly longer progression-free survival.